Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY announces Pelareorep ≥50% ORR & mPFS Improvements

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 04, 2023 11:42am

216 Views

Post# 35479142

RE:RE:RE:RE:RE:RE:RE:RE:ONCY announces Pelareorep ≥50% ORR & mPFS Improvements

The Phase 2 Bracelet-1 results provided good news showing that pelareorep works as a single agent, with a significant PFS of 86%, thus making pelareorep now eligible for an Accelerated Approval on its own and in combination with other I/O agents. ONCY has also demonstrated pelareorep MOA in remodeling the TME and expanding T-cells to overcome T-cell exhaustion and escape that other I/O agents currently face.

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?